

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2023

FOR

ASAN MEDICAL LIMITED

Dattani
Chartered Accountants
Scottish Provident House
76/80 College Road
Harrow
Middlesex
HA1 1 BQ

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

ASAN MEDICAL LIMITED
COMPANY INFORMATION
FOR THE YEAR ENDED 31 MAY 2023

DIRECTORS:

Dr A Maini
Mrs A Maini

SECRETARY:

REGISTERED OFFICE:

75 Burbage Road
Herne Hill
London
SE24 9HB

REGISTERED NUMBER:

10172112 (England and Wales)

ACCOUNTANTS:

Dattani
Chartered Accountants
Scottish Provident House
76/80 College Road
Harrow
Middlesex
HA1 1 BQ

ASAN MEDICAL LIMITED (REGISTERED NUMBER: 10172112)

BALANCE SHEET
31 MAY 2023

	Notes	31.5.23 £	£	31.5.22 £	£
FIXED ASSETS					
Property, plant and equipment	4		181		241
CURRENT ASSETS					
Debtors	5	1,442		1,442	
Cash at bank		<u>47,365</u>		<u>27,920</u>	
		48,807		29,362	
CREDITORS					
Amounts falling due within one year	6	<u>9,836</u>		<u>4,439</u>	
NET CURRENT ASSETS			<u>38,971</u>		<u>24,923</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>39,152</u>		<u>25,164</u>
CAPITAL AND RESERVES					
Called up share capital			2		2
Retained earnings			<u>39,150</u>		<u>25,162</u>
SHAREHOLDERS' FUNDS			<u>39,152</u>		<u>25,164</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 December 2023 and were signed on its behalf by:

Dr A Maini - Director

The notes form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023

1. STATUTORY INFORMATION

Asan Medical Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - 1).

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2023

4. PROPERTY, PLANT AND EQUIPMENT

	Plant and machinery etc £	
COST		
At 1 June 2022		
and 31 May 2023		429
DEPRECIATION		
At 1 June 2022		188
Charge for year		60
At 31 May 2023		248
NET BOOK VALUE		
At 31 May 2023		181
At 31 May 2022		241

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.5.23	31.5.22
	£	£
Other debtors	<u>1,442</u>	<u>1,442</u>

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.5.23	31.5.22
	£	£
Taxation and social security	3,999	175
Other creditors	<u>5,837</u>	<u>4,264</u>
	<u>9,836</u>	<u>4,439</u>

7. RELATED PARTY DISCLOSURES

During the year the company paid dividends of £3,000 to the directors.

8. ULTIMATE CONTROLLING PARTY

The Company is under the control of both directors.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.